Table 3.
Adverse events and safety data during the treatment in two groups.
| Event | Dulaglutide Combined with CRD Therapy (n = 35) | CRD Therapy (n = 33) |
|---|---|---|
| No. of Participants (%) | No. of Participants (%) | |
| Adverse events-related discontinuation | 2 (5.71) | 0 (0) |
| Patients with ≥1 GI TEAE | 13 (37.14) | 0 (0) |
| Nausea | 8 (22.86) | 0 (0) |
| Vomiting | 7 (20.00) | 0 (0) |
| Diarrhea | 0 (0) | 0 (0) |
| Constipation | 4 (11.43) | 0 (0) |
| Loss of appetite | 4 (11.43) | 0 (0) |
| Abdominal distension | 2 (5.71) | 0 (0) |
| Abdominal pain | 1 (2.86) | 0 (0) |
| Eructation | 1 (2.86) | 0 (0) |
| Sensations of hunger | 0(0) | 3(9.09) |
| Hypoglycemia | 0 (0) | 0 (0) |
| Dizziness | 3 (8.57) | 1 (3.03) |
| Injection site reaction | 0 (0) | 0 (0) |
| Upper respiratory tract infection | 0 (0) | 0 (0) |
| Headache | 1 (2.86) | 0 (0) |
| Nasopharyngitis | 0 (0) | 0 (0) |
CRD, calorie-restricted diet; GI, gastrointestinal; TEAE treatment-emergent adverse event.